文献速递间质性肺疾病

尼达尼布对进行性纤维化性间质性肺疾病不同入组标准亚组的影响

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
PubMed 文献 · Eur Respir J · 2022-02-03

INBUILD试验比较尼达尼布与安慰剂在进行性纤维化性间质性肺疾病患者中的疗效。研究按ILD进展入组标准分三组,分析52周内FVC下降率。结果显示尼达尼布在各亚组均降低FVC下降率,且相对效应一致。

要点

  • 尼达尼布在各进展标准亚组中均降低FVC年下降率。
  • 安慰剂组FVC下降幅度随入组标准不同而异。
  • 尼达尼布相对安慰剂的疗效在各亚组间一致。

核心结论

  • INBUILD试验的入组标准能有效识别进行性纤维化性ILD患者。
  • 尼达尼布在基于ILD进展标准的各亚组中均降低FVC下降率。

研究设计与样本

  • INBUILD试验的事后亚组分析,比较尼达尼布与安慰剂。
  • 受试者为非IPF的纤维化性ILD且符合24个月内进展标准。
  • 按FVC下降或症状加重及HRCT纤维化扩展分为A、B、C三组。

主要发现

  • 安慰剂组总体人群A、B、C组52周FVC年下降率分别为-241.9、-133.1、-115.3 mL(交互p=0.0002)。
  • UIP样纤维化模式者A、B、C组FVC年下降率分别为-288.9、-156.2、-100.1 mL(交互p=0.0005)。
  • 尼达尼布在A组的绝对效应大于B组或C组,但相对效应在各亚组间一致(异质性p>0.05)。

关键数值与推荐

  • A组:FVC相对下降≥10%预计值。
  • B组:FVC相对下降≥5-<10%预计值伴呼吸道症状加重和/或HRCT纤维化扩展。
  • C组:仅呼吸道症状加重和HRCT纤维化扩展。

临床怎么用

  • 对符合INBUILD入组标准的进行性纤维化性ILD患者可考虑使用尼达尼布。
  • 不同进展标准亚组均可从尼达尼布治疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The INBUILD trial investigated nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs). We investigated the decline in forced vital capacity (FVC) in subgroups based on the inclusion criteria for ILD progression. METHODS: Subjects had a fibrosing ILD other than idiopathic pulmonary fibrosis and met the following criteria for ILD progression within the 24 months before screening despite management deemed appropriate in clinical practice: Group A, relative decline in FVC ≥10% predicted; Group B, relative decline in FVC ≥5-<10% predicted with worsened respiratory symptoms and/or increased extent of fibrosis on high-resolution computed tomography (HRCT); Group C, worsened respiratory symptoms and increased extent of fibrosis on HRCT only. RESULTS: In the placebo group, the rates of FVC decline over 52 weeks in Groups A, B and C, respectively, were -241.9, -133.1 and -115.3 mL per year in the overall population (p=0.0002 for subgroup-by-time interaction) and -288.9, -156.2 and -100.1 mL per year among subjects with a usual interstitial pneumonia (UIP)-like fibrotic pattern on HRCT (p=0.0005 for subgroup-by-time interaction). Nintedanib had a greater absolute effect on reducing the rate of FVC decline in Group A than in Group B or C. However, the relative effect of nintedanib versus placebo was consistent across the subgroups (p>0.05 for heterogeneity). CONCLUSIONS: The inclusion criteria used in the INBUILD trial, based on FVC decline or worsening of symptoms and extent of fibrosis on HRCT, were effective at identifying patients with progressive fibrosing ILDs. Nintedanib reduced the rate of decline in FVC across the subgroups based on the inclusion criteria related to ILD progression.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Maher TM, Brown KK, Kreuter M, et al. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. Eur Respir J. 2022. PMID: 34210788. doi:10.1183/13993003.04587-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。